Spero Therapeutics Inc (SPRO)
1.445
+0.04
(+2.85%)
USD |
NASDAQ |
Apr 23, 16:00
1.445
0.00 (0.00%)
After-Hours: 20:00
Spero Therapeutics Cash from Financing (Quarterly): 0.001M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 0.001M |
September 30, 2023 | 0.22M |
June 30, 2023 | 0.00 |
March 31, 2023 | 0.00 |
December 31, 2022 | 14.18M |
September 30, 2022 | 6.131M |
June 30, 2022 | -53.68M |
March 31, 2022 | 3.814M |
December 31, 2021 | 50.35M |
September 30, 2021 | 29.22M |
June 30, 2021 | 0.168M |
March 31, 2021 | 4.309M |
December 31, 2020 | 16.09M |
September 30, 2020 | 77.22M |
Date | Value |
---|---|
June 30, 2020 | 7.39M |
March 31, 2020 | 30.19M |
December 31, 2019 | 5.599M |
September 30, 2019 | 0.01M |
June 30, 2019 | 8.963M |
March 31, 2019 | 1.568M |
December 31, 2018 | -0.178M |
September 30, 2018 | 69.90M |
June 30, 2018 | -0.196M |
March 31, 2018 | 0.00 |
December 31, 2017 | 74.68M |
September 30, 2017 | -0.411M |
June 30, 2017 | -1.161M |
March 31, 2017 | 43.00M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-53.68M
Minimum
Jun 2022
77.22M
Maximum
Sep 2020
10.54M
Average
5.599M
Median
Dec 2019
Cash from Financing (Quarterly) Benchmarks
Retractable Technologies Inc | -0.1364M |
OptiNose Inc | 0.004M |
scPharmaceuticals Inc | 0.467M |
electroCore Inc | 0.00 |
Equillium Inc | 0.079M |
Cash from Financing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -17.49M |
Free Cash Flow | -33.00M |
Free Cash Flow Per Share (Quarterly) | -0.3231 |
Free Cash Flow to Equity (Quarterly) | -17.49M |
Free Cash Flow to Firm (Quarterly) | -17.49M |
Free Cash Flow Yield | -43.09% |